ACAD vs EXC · P/E 15, rev $576.0M vs P/E 17, rev $24.26B
ACADIA Pharmaceuticals Inc (ACAD) versus Exelon Corporation (EXC) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
Exelon Corporation (EXC) is a utilities - regulated electric company listed on NASDAQ.
Latest reported ACAD revenue for 2026-06-30 was $576.0M. Net income was $35.1M. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Latest reported EXC revenue for 2025-12-31 was $24.26B. Net income was $2.77B. Revenue was up 5.3% from 2024-12-31 to 2025-12-31. EXC currently screens at market cap $47.33B and trailing P/E 16.8.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. EXC currently screens at market cap $47.33B and trailing P/E 16.8.
Not investment advice. Open the ACAD and EXC stock pages for the full models.
Not investment advice.